Clinical summary
Summary
This study is recruiting people who have verified gastrointestinal stromal tumour (GIST) with a high risk of recurrence, despite removal of all macroscopic GIST tissue during surgery and having received 3 years of adjuvant imatinib. Study participants will be randomly allocated to either Arm A or Arm B. In Arm A (Experimental), participants will continue receiving imatinib (400mg/day for 24 months). In Arm B, participants will stop receiving imatinib. All participants will be followed up using blood tests and scans of the abdomen.Conditions
This trial is treating patients with gastrointestinal stromal tumours.
Cancer
Sarcoma
Age
18 - 100
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Heikki Joensuu
Scientific Title
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study